I am an A/Prof at Monash University and co-leader of the Analytical and Structural Neuropharmacology group in the Drug Discovery Biology Theme at Monash Institute of Pharmaceutical Sciences. My research has been instrumental in the development, dissemination, and uptake of three major paradigms of GPCR drug action: 1) allosteric modulation, which led to my receipt of the 2015 Thomson Reuters Australia Citation & Innovation Award, Pharmacology and Toxicology. 2) biased signalling, which led me to secure a collaborative work with US-based biotech Karuna Therapeutics. 3) bitopic ligands, which led to my receipt of the 2012 BPS/ASCEPT Outstanding New Investigator Award, and 2012 ASCEPT Denis Wade Johnson & Johnson New Investigator Award, and the implementation of the concept in the most prestigious textbooks, the Goodman & Gilman's: The Pharmacological Basis of Therapeutics. In the last 10 years, I have had a sustained record of research income, totalling $6.5M (>75% as CIA).

Dr. Arsalan Yousuf is a Lecturer in Sydney Pharmacy School, The University of Sydney. His research area of interest revolves around targeting membrane GPCR's involved in regulating pain and addiction like Opioid receptors, GABA-B receptors and their interaction with ion channels. His expertise focusses on patch clamp electrophysiology, slice electrophysiology, immunohistochemistry, molecular biology.

Prof. Yan Zhang received his Ph.D. in Organic Chemistry from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, in 2013. He subsequently conducted postdoctoral research with Dr. Georgios Skiniotis at the University of Michigan Life Sciences Institute (2013–2017) and the Department of Molecular & Cellular Physiology, Stanford University School of Medicine (2017–2018). In 2018, he joined the Zhejiang University School of Medicine as a tenure-track Professor and Principal Investigator, and was promoted to full Professor in 2022. His group leverages cryo-electron microscopy and computationally guided protein design to dissect receptor activation and signaling, and to pioneer new strategies for modulating GPCR function beyond traditional small-molecule drugs. By developing engineered proteins, nanobodies, and allosteric modulators, his team explores novel avenues to precisely regulate receptor activity. His laboratory has elucidated high-resolution structures of diverse GPCR signaling complexes, uncovering unexpected mechanisms of receptor regulation and pharmacology.

Dalei Wu received a B.S degree in Biotechnology from Shandong University in 2003, and a Ph.D. in Drug Design from Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2008. He spent three years at University of California, Davis training in Environmental Toxicology as a postdoc, and another five years at Sanford-Burnham Medical Research Institute at Orlando in Structural Biology. In 2016, he returned to China and was recruited to Shandong University. His lab mainly works on the structures and functions of transcription factors (especially the bHLH-PAS family), and on the discovery of small-molecule compounds targeting these proteins with potential therapeutic effects. His studies have been published on journals including Nature, Nature Chemical Biology, Nature Communications, PNAS, JACS and JMC.

Dr. D. Figueredo received her B.A. degree (1995, Biochemistry) from Faculty of Biology, Havana University, Cuba, and both her MSc (1995, Biomedicine) and PhD (1999 Pharmaceutical Sciences) degree from National Center for Scientific Research in Havana, and most of the results were done in the Department of Toxicology at the Free University in Amsterdam. Postdoctoral training in Molecular Toxicology and pharmacology was completed at the Faculty of Pharmacy in Toronto, Canada. She has been referee of scientific journals related with pharmacology. Other previous academic appointments include lecturer in different international meeting. She has been the recipient of National Award of Pharmacology twice from the Cuban Pharmacology Society. She worked as Expert for the evaluation of preclinical platform in South Africa. (CSIR). She is the focal point to the World Health Organization network for regulatory cooperation of herbal medicines (IRCH). She is a membership committee of International Union of Pharmacology (IUPHAR). She is the secretary of Latin-American Network of Pharmacogenetic. She is currently the Vice president of Cuban Pharmacology Society. At present she works in the Cuba Regulatory Agency as senior researcher, she is in charge of the evaluation of safety and efficacy of traditional, integrative and complementary medicines for registering. Dr. Remirez research is described in over 60 published research reports.

Dangge Wang is a principal investigator at Shanghai Jiao Tong University School of Medicine, Shanghai General Hospital. He obtained his B.S. degree at Fudan University and Ph.D degree at Shanghai Institute of Materia Medica, Chinses Academy of Sciences. He has published more than 28 peer-reviewed papers in journals including Sci Immunol, Natl Sci Rev, Sci Adv, Nat Commun, Adv Mater, Nano Today, ACS Nano, Nano Lett, Adv Funct Mater and so on. He has applied more than 10 patents with 6 authorized. His group focuses on improving immunotherapy efficiency in various types of cancer by smart drug delivery systems. He has made a series of contributions to targeted drug delivery systems including the design, construction and mechanistic study of novel nanosized drug delivery systems with higher efficacy and lower toxicity.